14773-50-3

Basic information

• Product Name: 3-ethoxypyridine
• Synonyms: 3-ethoxypyridine
• CAS NO: 14773-50-3
• Molecular Formula: C₇H₉NO
• Molecular Weight: 123
• Mol File: 14773-50-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-ethoxypyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-ethoxypyridine(14773-50-3)
• EPA Substance Registry System: 3-ethoxypyridine(14773-50-3)

Safety Data

• Hazardous Substances Data: 14773-50-3(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Tetrahedron Letters, 8, p. 771, 1967 DOI: 10.1016/S0040-4039(00)71559-0

Upstream product

• 109-00-2 3-HYDROXYPYRIDINE 
• 74-96-4 ethyl bromide 
• 64-17-5 ethanol 
• 626-55-1 3-Bromopyridine 
• 141-52-6 sodium ethanolate 
• 2457-47-8 3,5-dichloropyridine 
• 65520-08-3 3-bromopyridine hydrochloride 
• 142303-36-4 6-cyano-2,2-dimethyl-4-(pyridin-2-yl)-2H-1,3-benzoxazine 
• 626-60-8 3-Chloropyridine 
• 1851-22-5 3-chloropyridine-N-oxide 
• 102074-24-8 3-ethoxypyridine-1-oxide 
• 75-03-6 ethyl iodide 
• 108-01-0 2-(N,N-dimethylamino)ethanol 
• 105-58-8 Diethyl carbonate 

Downstream Products

• 102074-24-8 3-ethoxypyridine-1-oxide 
• 109-00-2 3-HYDROXYPYRIDINE 
• 74037-50-6 3-ethoxy-2-nitropyridine 
• 81376-79-6 3-Ethoxy-2-trimethylsilylpyridine 
• 81376-87-6 3-Ethoxy-4-trimethylsilylpyridine 
• 81376-83-2 (3-Ethoxy-pyridin-2-yl)-(4-methoxy-phenyl)-methanol 
• 81376-84-3 3-ethoxy-2-pyridine aldehyde 
• 1025993-82-1 [(S)-1-(3-Ethoxy-pyridine-2-carbonyl)-2-methyl-propyl]-carbamic acid benzyl ester 
• 147645-89-4 3-ethoxy-4-phenylsulfonylmethylpyridinium 1-dicyanomethylide 
• 6602-32-0 2-bromo-pyridin-3-ol 
• 89943-11-3 2-amino-5-ethoxypyridine 
• 89694-54-2 2-bromo-3-ethoxypyridine 
• 137347-01-4 3-ethoxy-2-bromo-6-nitro-pyridine 
• 16867-03-1 2-amino-3-hydroxypyridine 

Relevant articles and documents

Mustard Carbonate Analogues as Sustainable Reagents for the Aminoalkylation of Phenols

N,N-dialkyl ethylamine moiety can be found in numerous scaffolds of macromolecules, catalysts, and especially pharmaceuticals. Common synthetic procedures for its incorporation in a substrate relies on the use of a nitrogen mustard gas or on multistep syntheses featuring chlorine hazardous/toxic chemistry. Reported herein is a one-pot synthetic approach for the easy introduction of aminoalkyl chain into different phenolic substrates through dialkyl carbonate (β-aminocarbonate) chemistry. This new direct alcohol substitution avoids the use of chlorine chemistry, and it is efficient on numerous pharmacophore scaffolds with good to quantitative yield. The cytotoxicity via MTT of the β-aminocarbonate, key intermediate of this synthetic approach, was also evaluated and compared with its alcohol precursor.

COMBINATIONS FOR TREATMENT OF NAFLD/NASH AND RELATED DISEASES

A method for treating fatty liver disease and related diseases or disorders with a therapeutically effective amount of a composition comprising from about 25 mg to about 1200 mg of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5- carboxamide or a pharmaceutically acceptable salt thereof, and from about 5 mg to about 40 mg of 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6- methoxypyridin-2-yl)benzoic acid or a pharmaceutically acceptable salt thereof.

Combinations For Treatment Of NASH/NAFLD And Related Diseases

The combination of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or pharmaceutically acceptable salt thereof, and 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4′-piperidine]-1′-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or pharmaceutically acceptable salt thereof, for treatment of diseases, including non-alcoholic steatohepatitis (NASH), in mammals are described herein.

COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES

In part, the invention provides a new combination comprising (1) a GLP-1R agonist and (2) an ACC inhibitor or a DGAT2 inhibitor, or a KHK inhibitor or FXR agonist. The invention further provides new methods for treating diseases and disorders, for example, fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepotitis with cirrhosis, and nonalcoholic steatohepatitis with cirrhosis and with hepatocellular carcinoma or with a metabolic-related disease, obesity, and type 2 diabetes, for example, using the new combination described herein.

DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS

Compounds of Formula (I) that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

Novel protein kinase inhibitors related to tau pathology modulate tau protein-self interaction using a luciferase complementation assay

The current number of drugs available for the treatment of Alzheimer's disease (AD) is strongly limited and their benefit for therapy is given only in the early state of the disease. An effective therapy should affect those processes which mainly contribu

Synthesis method of heterocyclic compound 3-methoxypyridine

The invention discloses a synthesis method of a heterocyclic compound 3-methoxypyridine. The method comprises the following steps: putting raw materials, i.e., 3-halogenated pyridine, hydrogen peroxide and acetic acid into a three-mouth flask, carrying out reaction for 4-8h at the temperature of 40-80 DEG C under the condition of stirring, recovering the acetic acid, adding a saturated sodium carbonate solution and stirring to enable a system to be alkaline, evaporating to remove water, then adding chloroform for washing, and carrying out vacuum distillation to obtain N-oxide-3-halogenated pyridine; respectively adding the N-oxide-3-halogenated pyridine, metal salt of alkyl alcohol, a catalyst A and alcohol into the three-mouth flask, carrying out reflux reaction for 5-8h under the condition of stirring, then cooling, neutralizing a product to be neutral, and carrying out distillation to obtain N-oxide-3-alkyloxypyridine; respectively adding the N-oxide-3-alkyloxypyridine, ferric trichloride, hydrazine hydrate, activated carbon and ethanol into the three-mouth flask, carrying out reaction at the temperature of 70 DEG C for 3h, cooling to room temperature, and carrying out vacuum distillation to obtain the 3-methoxypyridine. The synthesis method is high in intermediate conversion rate, mild in reaction conditions, safe in operation, low in price of raw materials and easy in raw material obtaining, thus being suitable for industrial production.

3,5-DICHLORO-4-PYRIDINECARBONITRILE AS A KEY REAGENT IN A SYNTHESIS OF COPPER CONTAINING AMINE OXIDASE INHIBITORS

Various synthetic approaches to 3,4,5-trifunctionalized pyridine derivatives useful as benzylamine oxidase inhibitors are extensively explored.Fully satisfactory preparations of the inhibitors 3,5-diethoxy-4-aminomethylpyridine (4), 3,5-bis(3-hydroxypropoxy)-4-aminomethylpyridine (11), 3,5-bis(4-hydroxybutoxy)-4-aminomethylpyridine (12) and 3-ethoxy-5-phenylmethoxy-4-aminomethylpyridine (16), all in the form of dihydrochloride salt, using 3,5-dichloro-4-pyridinecarbonitrile as key precursor, are reported.

1,3-benzoxazine derivatives, their production and use

A new compound of the formula: STR1 wherein STR2 is an optionally substituted benzene ring; R1 is a carbocyclic or heterocyclic group which is linked to the 4-position of the 1,3-benzoxazine ring through a carbon-carbon bond, a hydrocarbon resi